Social Media Strategies Virtual Conference Agenda

Social Media Strategies for Drug & Device Companies
Practical Tips and Tools to Use in the Absence of FDA Guidance

Thursday, May 30, 2013 • 10:00 a.m. - 2:30 p.m. EDT

10:00 a.m. – 11:00 a.m.

The Current State of Regulation of Social Media and Digital Communications
Since November 2009 the FDA has had social media guidance on its radar. But as more and more people join Facebook, scour WebMd for answers, and tweet about their latest thoughts on their medication, the FDA has been relatively silent. Industry cannot wait. This session provides the latest status on guidance and advice on how industry can move forward in its absence.

Attendees will learn:

  • What is FDA’s current plan?
  • What has changed since the November 2009 public meeting?
  • How can Industry move forward effectively with minimal risk?

Glenn Byrd, Senior Director, Regulatory Affairs, MedImmune, former Branch Chief, Advertising and Promotional Labeling, CBER, FDA

11:00 a.m. – 12:00 p.m.

Case Study: Moderating Facebook Pages For Adverse Events and Maintaining Page Security
Facebook and adverse event reporting have been linked as a regulatory and compliance concern ever since drug and biologic firms created Facebook pages. The initial concern was that a company would be held responsible for monitoring and following up on a comment that suggested an adverse event. But, what’s the difference between an actual adverse event and patient dissatisfaction? The lines are no clearer as 2011 nears a close. Now, in the wake of the recent hack into Pfizer’s Facebook page, there’s a larger issue of security and crisis management.

Attendees will learn:

  • Best practices for moderating a Facebook page to allow for open discussion while complaining with AER requirements
  • Where is the dividing line between dissatisfaction and an adverse event?
  • After the Pfizer hack, will firms increase or decrease their Facebook usage?

Jim Dayton, Senior Director, Emerging Media at Intouch Solutions

12:00 p.m. – 12:30 p.m.

We’re Not “Big Pharma” How To Replicate The Success of AstraZeneca’s Tweet Chats and Eli Lilly’s Lillypad Blog?
Now every company is a multi-billion dollar, global powerhouse with an extensive RA department and a Madison Avenue agency.  But everyone is looking to catch the social media wave, no matter what size your revenue stream is.  This session will delve into how small and mid-sized firms can start and expand social media programs while adhering to the little guidance the FDA has provided.

Attendees will learn:

  • Is a tweet a tweet no matter who big the tweeter is?
  • Best practices for bare bones media departments to improve their social media programs and still maintain compliance

Michael Spitz, Vice President, Digital Strategy, Ignite Health

12:30 p.m. – 1:30 p.m.

How To Keep Your Pharma and Device Facebook Page Alive
Many companies are concerned about the changes to Facebook's policy and whether or not they can manage their existing Facebook pages or create new ones. The "open wall" makes it much more challenging to have control over the content that appears there. But the changes will require Pharma to actually participate in this Social Media venue in the way it was meant to be used - as a two-way dialogue, and there are positive opportunities that can come from that experience.

Attendees will learn:

  • Look at the evolution of the Facebook platform and Pharma's involvement
  • Discuss will need to be restructured in our organizations in order to participate
  • Share some Best Practices in the marketplace
  • Take comments from session participants on ways they are working to bring success to their organizations

Zoë Dunn, President, Hale Advisors, Inc.

1:30 p.m. – 2:30 p.m.

A Snapshot of Social Media in Pharma: The Why, What and How
What exactly is pharma doing in social media, and what are the driving factors? How are companies structuring and staffing their efforts? What is holding the industry back? This session will provide a snapshot — in the form of benchmarks, interviews and best practices — of the current social media landscape in pharma, based on brand new research by market intelligence firm Cutting Edge Information.

Attendees will learn:

  • The differences between what corporate- and brand-level social media looks like
  • Best practices for developing a social media structure, and how to staff it
  • Ratings of the biggest obstacles to more widespread social media adoption

Casey Ferrell, Market Research Analyst, Cutting Edge Information

* This virtual broadcast is self paced. You can use the software tools on your screen at anytime to pause the presentation for as long as you like, just press play to resume where you left off.